Mental Health Parity Act (MHPAEA) Explained" class="auto-link">mhpaea-parity-rights">Insurance Denied Addiction Treatment — MHPAEA Parity Rights

Substance use disorder is a brain disease — chronic, relapsing, and treatable. The science is clear. The clinical guidelines are clear. Federal law is clear. And yet insurance companies deny addiction treatment every single day, forcing people who have already taken the courageous step of seeking help to fight for access to care. If that is where you are right now, this guide is for you.

Why Addiction Treatment Claims Are Denied

• Residential treatment (rehab) denied: Insurer says outpatient treatment is adequate, even when your treatment team has assessed you as needing the structure and safety of residential care.
• Inpatient detoxification denied or cut short: Insurer terminates inpatient detox coverage before medical stabilization is complete.
• Medication-Assisted Treatment (MAT) denied: Buprenorphine (Suboxone), methadone, naltrexone (Vivitrol), or other FDA-approved medications are denied or require Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization that creates dangerous delays.
• Number of intensive outpatient (IOP) sessions denied: Insurer imposes session limits on IOP or partial hospitalization programs (PHP).
• "No longer medically necessary": Concurrent review denies continued stay during residential treatment, citing inadequate clinical criteria being met.
• Relapse-related denial: Coverage is denied or terminated because the patient has relapsed — arguably the most harmful form of denial, given that relapse is a clinical feature of the disease.

Federal Law: MHPAEA Is Your Foundation

The Mental Health Parity and Addiction Equity Act (MHPAEA) is the most powerful tool in your appeal arsenal. It requires that health plans providing mental health and substance use disorder benefits must:

• Apply the same quantitative treatment limits to SUD treatment as to comparable medical/surgical benefits. If your plan covers unlimited medical hospitalizations, it cannot cap SUD residential treatment at 30 days.
• Apply non-quantitative treatment limits (NQTLs) — like prior authorization requirements, medical necessity criteria, and step therapy — no more restrictively to SUD than to medical/surgical benefits.

The 2024 MHPAEA final rule significantly strengthened enforcement, requiring insurers to conduct comparative parity analyses and make them available to enrollees upon request. Request your insurer's NQTL comparative analysis in writing — their internal criteria and how they compare to medical benefits. Disparities in that document support your appeal and regulatory complaints.

The ASAM Criteria: Your Clinical Standard

The American Society of Addiction Medicine (ASAM) Criteria (formerly known as ASAM Patient Placement Criteria) is the national standard for determining appropriate level of care for substance use disorders. It defines:

• Level 0.5: Early intervention
• Level 1: Outpatient services
• Level 2.1/2.5: Intensive outpatient/partial hospitalization
• Level 3.1–3.7: Residential treatment
• Level 4: Medically managed intensive inpatient

If your treatment provider used the ASAM Criteria to recommend a specific level of care, that recommendation carries substantial clinical weight. An insurer denying residential care that an ASAM-assessed clinician has recommended must explain why their medical necessity criteria differ from this national standard.

Medication-Assisted Treatment: A Priority Appeal

Denials of buprenorphine, methadone, or naltrexone for opioid use disorder are particularly dangerous. These are FDA-approved, evidence-based treatments that significantly reduce mortality. The American Society of Addiction Medicine, Substance Abuse and Mental Health Services Administration (SAMHSA), and major medical organizations all support MAT as the standard of care for opioid use disorder.

If MAT is denied or delayed by prior authorization:

• Request expedited prior authorization given the life-threatening nature of untreated opioid use disorder.
• Cite SAMHSA guidelines and ASAM guidelines supporting MAT as first-line treatment.
• Document the danger of treatment delay (overdose risk).

Building Your Appeal

1. Treating physician or addiction specialist letter — ASAM level-of-care assessment, clinical rationale for the recommended treatment setting.
2. ASAM Criteria documentation — showing which level of care criteria were met.
3. Parity argument — cite MHPAEA, request the NQTL comparative analysis.
4. ASAM/SAMHSA clinical guidelines supporting the recommended care level.
5. Documentation of prior treatment — previous treatment attempts and outcomes to establish treatment history.
6. Urgency/safety argument — particularly for detox and MAT, where denial creates direct risk of harm.

Regulatory Complaints

If your insurer is violating parity requirements:

• File with your State Department of Insurance
• File with EBSA (Employee Benefits Security Administration) for employer plans
• Contact your state attorney general — many have active parity enforcement divisions

Advocacy Resources

• Faces & Voices of Recovery (facesandvoicesofrecovery.org) — recovery advocacy
• Shatterproof (shatterproof.org) — addiction treatment access advocacy and a treatment locator
• SAMHSA National Helpline — 1-800-662-4357 (free, confidential, 24/7)
• Legal Action Center (lac.org) — legal advocacy for parity violations

Fight Back With ClaimBack

Seeking treatment for addiction is one of the most important decisions a person can make — and your insurance company does not get to stand in the way. ClaimBack helps individuals and families build parity-grounded, clinically documented appeals for addiction treatment denials.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Insurance Ombudsman Guide — When to Escalate Beyond Your Insurer